Komori
Share Issuance and Disposal4586Medrx Co.,Ltd.Medicines

Notice of Completion of Exercise and Monthly Exercise Status of the 35th Series of Stock Acquisition Rights with an Exercise Price Adjustment Clause, Issued Through a Third-Party Allotment

During November 2026, 2,839,600 shares' worth of the 35th Series of Stock Acquisition Rights with an exercise price adjustment clause were exercised, completing the exercise of all 147,820 rights. The number of rights remaining unexercised is now 0.

Worth reading
70In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2839600
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly Exercise Status and Exercise Completion Report for Stock Acquisition Rights with an Exercise Price Adjustment Clause Issued Through a Third-Party Allotment

Who receives how much

Number of shares delivered during the month: 2,839,600 shares (2,839,600 new shares and 0 treasury shares transferred)

グロース・キャピタル株式会社: 147,820 rights

The lower thin line represents the existing number of shares to which these shares will be added.

Amount of funds to be raised

Estimated net proceeds: ¥718 million. Total amount paid in is Not disclosed

Existing Shares and Increase
+4.78%Rate of increase
71,307,500 shares74,147,100Shares

Exercise ratio under exercise restrictions: 4.78%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price: ¥44 on 2 November 2026 and ¥37 from 9 November 2026 onward. Details of the exercise price adjustment clause and the adjustment floor are Not disclosed
Number of Stock Acquisition Rights
Total rights issued: 147,820; rights exercised: 147,820; rights remaining unexercised: 0
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. Obtaining an independent third-party opinion and confirming shareholders' intentions are Not disclosed
Most recent equity financing
5 June 2026: Issuance of the 35th Series of Stock Acquisition Rights. Estimated net proceeds: ¥718 million
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly Exercise Status and Exercise Completion Report for Stock Acquisition Rights with an Exercise Price Adjustment Clause Issued Through a Third-Party Allotment
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 2,839,600 shares (2,839,600 new shares and 0 treasury shares transferred)
Amount of funds to be raisedEstimated net proceeds: ¥718 million. Total amount paid in is Not disclosed
Intended allotteeグロース・キャピタル株式会社: 147,820 rights
Dilution RateExercise ratio under exercise restrictions: 4.78%
Total number of issued shares71,307,500 shares (as of the end of the month preceding the subject month) → 74,147,100 shares (as of 17 November 2026)
Exercise priceExercise price: ¥44 on 2 November 2026 and ¥37 from 9 November 2026 onward. Details of the exercise price adjustment clause and the adjustment floor are Not disclosed
Number of Stock Acquisition RightsTotal rights issued: 147,820; rights exercised: 147,820; rights remaining unexercised: 0
Procedures under the Corporate Code of ConductDescribes compliance with the exercise restrictions under Article 434 of the Listing Regulations. Obtaining an independent third-party opinion and confirming shareholders' intentions are Not disclosed
Most recent equity financing5 June 2026: Issuance of the 35th Series of Stock Acquisition Rights. Estimated net proceeds: ¥718 million
Items this document does not state (18)
Issue price and disposal priceTotal issue valueEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the exercise payment made on 17 November 2026 completed the exercise of all of these stock acquisition rights.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Exercise and Monthly Exercise Status of the 35th Series of Stock Acquisition Rights with an Exercise Price Adjustment Clause, Issued Through a Third-Party Allotment | Medrx Co.,Ltd. (4586) timely disclosure | Komori